Alnylam Pharmaceuticals, Inc.  

(Public, NASDAQ:ALNY)   Watch this stock  
Find more results for ALNY
75.57
-1.52 (-1.97%)
Sep 23 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 75.56 - 77.78
52 week 49.96 - 110.75
Open 77.04
Vol / Avg. 0.00/477,937.00
Mkt cap 6.35B
P/E     -
Div/yield     -
EPS -4.24
Shares 85.72M
Beta 2.39
Inst. own 89%
Nov 7, 2016
Q3 2016 Alnylam Pharmaceuticals Inc Earnings Release (Estimated) - 4:00PM EST - Add to calendar
Sep 28, 2016
Alnylam Pharmaceuticals Inc at Leerink Partners Rare Disease & IO Roundtable Series - 1:35PM EDT - Add to calendar
Sep 16, 2016
Alnylam Pharmaceuticals Inc at Bank of America Merrill Lynch Healthcare Conference
Sep 14, 2016
Alnylam Pharmaceuticals Inc at Morgan Stanley Global Healthcare Conference
Sep 13, 2016
2016 RNAi Roundtable: ALN-AS1 for the Treatment of Acute Hepatic Porphyrias Call
Aug 31, 2016
2016 RNAi Roundtable: ALN-CC5 for the Treatment of Complement-Mediated Diseases Call - Webcast
Aug 22, 2016
2016 RNAi Roundtable: Fitusiran for the Treatment of Hemophilia and Rare Bleeding Disorders Corporate Call - Webcast
Aug 10, 2016
Alnylam Pharmaceuticals Inc at Canaccord Genuity Growth Conference - Webcast
Aug 4, 2016
Q2 2016 Alnylam Pharmaceuticals Inc Earnings Call - Webcast
Aug 4, 2016
Q2 2016 Alnylam Pharmaceuticals Inc Earnings Release
More events from DailyFinance »    

Key stats and ratios

Q2 (Jun '16) 2015
Net profit margin -1034.89% -705.83%
Operating margin -1061.55% -720.27%
EBITD margin - -673.91%
Return on average assets -26.79% -23.52%
Return on average equity -31.61% -26.36%
Employees 369 -
CDP Score - -

Address

300 3rd St
CAMBRIDGE, MA 02142-1103
United States - Map
+1-617-5518200 (Phone)
+1-617-5518101 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Alnylam Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is engaged in developing therapeutics based on ribonucleic acid (RNA) interference (RNAi). It is focused on the use of its N-acetylgalactosamine (GalNAc)-conjugate strategy for delivery of small interfering RNAs (siRNAs). Its pipeline of investigational RNAi therapeutics focuses in three Strategic Therapeutic Areas (STArs): Genetic Medicines; Cardio-Metabolic Disease, and Hepatic Infectious Disease. Its Genetic medicines include Patisiran (ALN-TTR02), Revusiran (ALN-TTRsc), Fitusiran (ALN-AT3), ALN-CC5, ALN-AS1, and additional genetic programs, including ALN-AAT, ALN-GO1 and ALN-TMP. Products for Cardio-Metabolic Disease STAr include ALN-PCSsc and other cardio-metabolic disease programs ALN-AC3 and ALN-ANG targeting Angiopoetin-like 3 (ANGPTL3). Products for Hepatic Infectious Disease STAr include ALN-HBV, ALN-HDV and ALN-PDL. It also owns Enhanced Stabilization Chemistry, GalNAc-conjugate delivery platform.

Officers and directors

Michael W. Bonney Independent Chairman of the Board
Age: 57
Bio & Compensation  - Reuters
Barry E. Greene President
Age: 52
Bio & Compensation  - Reuters
Trading Activity - Yahoo Finance
John M. Maraganore Ph.D. Chief Executive Officer, Director
Age: 53
Bio & Compensation  - Reuters
David-Alexandre Gros M.D. Principal Financial Officer, Chief Business Officer, Senior Vice President
Age: 44
Bio & Compensation  - Reuters
Yvonne Greenstreet Chief Operating Officer, Executive Vice President
Age: 53
Bio & Compensation  - Reuters
Akshay K. Vaishnaw M.D. Ph.D. Executive Vice President - Research and Development ,Chief Medical Officer
Age: 53
Bio & Compensation  - Reuters
.. Bartlett Keating Senior Vice President - General Counsel, Secretary
Age: 61
Bio & Compensation  - Reuters
Michael P. Mason Principal Accounting Officer, Vice President, Treasurer
Age: 41
Bio & Compensation  - Reuters
Dennis A. Ausiello M.D. Independent Director
Age: 70
Bio & Compensation  - Reuters
John K. Clarke Independent Director
Age: 62
Bio & Compensation  - Reuters